Nanosizing: a formulation approach for poorly-water-soluble compounds.
暂无分享,去创建一个
Elaine Merisko-Liversidge | E. Merisko-Liversidge | G. Liversidge | E. R. Cooper | Gary G Liversidge | Eugene R Cooper
[1] J. Kreuter,et al. Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants , 1990 .
[2] Joseph P. Remington,et al. Remington's pharmaceutical sciences , 2016 .
[3] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[4] G. W. Pace,et al. Novel injectable formulations of insoluble drugs , 1999 .
[5] S. Venkatesh,et al. Role of the development scientist in compound lead selection and optimization. , 2000, Journal of pharmaceutical sciences.
[6] Lisbeth Illum,et al. Long circulating microparticulate drug carriers , 1995 .
[7] Jean W. Tom,et al. Particle formation with supercritical fluids—a review , 1991 .
[8] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[9] Papisov,et al. Theoretical considerations of RES-avoiding liposomes: Molecular mechanics and chemistry of liposome interactions. , 1998, Advanced drug delivery reviews.
[10] C. Lipinski. Poor aqueous solubility-an industry wide problem in drug discovery , 2002 .
[11] Lisbeth Illum,et al. Modification of the Copolymers Poloxamer 407 and Poloxamine 908 can Affect the Physical and Biological Properties of Surface Modified Nanospheres , 1998, Pharmaceutical Research.
[12] M. Lawrence,et al. Microemulsion-based media as novel drug delivery systems , 2000 .
[13] Hiroshi Maeda,et al. Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues , 1998, Japanese journal of cancer research : Gann.
[14] H. Bosch,et al. Sterile Filtration of NanoCrystal™ Drug Formulations , 1997 .
[15] T. Allen,et al. Liposomes , 2012, Drugs.
[16] R. W. Wood,et al. Nebulization of NanoCrystals™: Production of a Respirable Solid-in-Liquid-in-Air Colloidal Dispersion , 2004, Pharmaceutical Research.
[17] J Dressman,et al. Improving drug solubility for oral delivery using solid dispersions. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[18] G. Liversidge,et al. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs , 1995 .
[19] Clive G. Wilson,et al. Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape , 1982 .
[20] G Gregoriadis,et al. Engineering liposomes for drug delivery: progress and problems. , 1995, Trends in biotechnology.
[21] Stephen Byrn,et al. Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations , 1995, Pharmaceutical Research.
[22] B. Aungst,et al. Intestinal permeation enhancers. , 2000, Journal of pharmaceutical sciences.
[23] Y Zhang,et al. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[24] G. Na,et al. Physical Stability of Ethyl Diatrizoate Nanocrystalline Suspension in Steam Sterilization , 1999, Pharmaceutical Research.
[25] R. Juliano. Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions , 1988 .
[26] J. Dressman,et al. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. , 1997, Advanced drug delivery reviews.
[27] P Couvreur,et al. Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[28] H. Kusuhara,et al. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. , 1998, Journal of pharmaceutical sciences.
[29] R. Müller,et al. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.
[30] Roger A. Rajewski,et al. Cyclodextrins: Their Future in Drug Formulation and Delivery , 1997, Pharmaceutical Research.
[31] J. Breitenbach. Melt extrusion: from process to drug delivery technology. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[32] G. Liversidge,et al. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats , 1995 .
[33] S. Davis,et al. Nanoparticles in drug delivery. , 1987, Critical reviews in therapeutic drug carrier systems.
[34] A. Kibbe. Handbook of Pharmaceutical Excipients , 2009 .
[35] M. Nakano. Places of emulsions in drug delivery. , 2000, Advanced drug delivery reviews.
[36] J. Robinson,et al. Bioadhesive-based dosage forms: the next generation. , 2000, Journal of pharmaceutical sciences.
[37] M. Brewster,et al. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. , 1996, Journal of pharmaceutical sciences.
[38] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[39] Michael J Akers,et al. Excipient-drug interactions in parenteral formulations. , 2002, Journal of pharmaceutical sciences.
[40] F. Martin,et al. Tumoricidal effect of macrophages exposed to adriamycin in vivo or in vitro. , 1982, Cancer research.
[41] Beate Bittner,et al. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. , 2002, Current opinion in drug discovery & development.
[42] M. Woodle,et al. Controlling liposome blood clearance by surface-grafted polymers. , 1998, Advanced drug delivery reviews.
[43] Floyd. Top ten considerations in the development of parenteral emulsions. , 1999, Pharmaceutical science & technology today.
[44] R. Jain,et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[45] A. Serajuddin,et al. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. , 1999, Journal of pharmaceutical sciences.
[46] P. Couvreur,et al. Nanoparticles as microcarriers for anticancer drugs , 1990 .
[47] S. Arii,et al. Tumoricidal activity of Kupffer cells augmented by anticancer drugs. , 1992, Life sciences.
[48] V. Torchilin,et al. Biodegradable long-circulating polymeric nanospheres. , 1994, Science.
[49] J. M. Shaw,et al. Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs , 1996, Pharmaceutical Research.
[50] K. Johnston,et al. Solution-Based Particle Formation of Pharmaceutical Powders by Supercritical or Compressed Fluid Co2 and Cryogenic Spray-Freezing Technologies , 2001, Drug development and industrial pharmacy.
[51] Christos Reppas,et al. Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms , 2004, Pharmaceutical Research.
[52] M. Dewhirst,et al. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. , 2000, Cancer research.
[53] E. Bacon,et al. Pharmacokinetics and hepatic disposition of bis[1-(ethoxycarbonyl)propyl]5-acetylamino-2,4,6-triiodoisophthalate in rats and isolated perfused rat livers. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[54] R K Jain,et al. Delivery of Molecular Medicine to Solid Tumors , 1996, Science.